The Role of Pelvic Lymph Node Dissection During Radical Cystectomy for Bladder Cancer
|
|
- Alan Willis
- 6 years ago
- Views:
Transcription
1 Short Review The Role of Pelvic Lymph Node Dissection During Radical Cystectomy for Bladder Cancer EUGENIO BRUNOCILLA, REMIGIO PERNETTI and GIUSEPPE MARTORANA Department of Urology, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy Abstract. Background: Radical cystectomy is the standard treatment for patients with invasive bladder cancer. Many aspects regarding the role of concomitant pelvic lymph node dissection (PLND), its extension and the oncological impact are still under discussion. Materials and Methods: A detailed literature review is presented to assess the impact of pelvic lymph node dissection during radical cystectomy in terms of staging and therapeutic procedure. Analysis of evidence: The study presented the role of imaging in the assessment of lymph node status, the anatomical account of bladder lymphatic drainage and the techniques for dissection. The evidence from the literature examined showed that pathological stage of the bladder, the extent of PLND in both node-negative and - positive disease, the lymph node density and the extracapsular involvement of metastatic lymph nodes are significant independent prognostic factors for disease-free survival. Conclusion: Radical cystectomy with bilateral pelvic iliac lymphadenectomy is a standard treatment for high-grade, invasive bladder cancer, providing the best survival outcomes and the lowest local recurrence rates. Even if the precise extent of lymph node dissection is still not standardized, many studies support a more extended lymphadenectomy to obtain better cancer-specific survival rates without significantly increasing the morbidity or mortality of the surgery. The concept of lymph node density may become a useful prognostic variable in high-risk node-positive patients. Carcinoma of the bladder represents the fourth most frequent cancer in men and the eighth most frequent malignancy in women in the U.S.A. (1). Its incidence increases with age, peaking between the sixth and seventh decade of life, and is Correspondence to: Dr. Remigio Pernetti, Augusto Murri 63, 40137, Bologna, Italy. Tel: , r.pernetti@virgilio.it Key Words: Bladder cancer, extented lymphadenectomy, lymph node metastasis, radical cystectomy, lymph node density, cancerspecific survival, short review. three times more frequent in men than in women. Risk factors for bladder cancer can be divided into three groups: the most frequent is lifestyle environmental exposure (aromatic amines, cigarette smoking, nitrites and nitrates and acrolein), followed by genetic and molecular abnormalities, and chemical and/or chronic inflammation (indwelling catheters, Schistosoma haematobium infestation and pelvic radiotherapy). At the initial diagnosis of bladder cancer, approximately two thirds of the cases present as non-invasive tumours (stages Ta, T1 or tumours in situ [Tis, CIS]), but as many as 50-70% of the superficial tumours will recur and about 15% will progress to invasive disease (2). Moreover, approximately 20-30% of patients with stage T1-T4 N0 M0 bladder cancer who undergo radical cystectomy and pelvic lymph node dissection (PLND) are found to have lymph node disease (3, 4). The standard treatment for bladder cancer invading the muscolaris propria in male patients is radical cystoprostatectomy, while anterior pelvic exenteration (including the bladder, urethra, uterus and posterior vaginal wall with/without anterior vaginal wall) is the surgical treatment in female patients. Lymph node involvement is the most important prognostic variable in determining patient outcome following radical cystectomy. Pelvic lymphadenectomy should, thus, be the standard approach in all cases of radical cystectomy, even if many aspects regarding the extension and oncological impact of PLND are still under debate. Materials and Methods A systematic literature review was undertaken. The electronic databases Pubmed/Medline, Cochrane and Embase were searched using the following key words: bladder cancer, transitional cell carcinoma, radical cystectomy, lymph node dissection and lymph node metastasis. From Medline/Pubmed, 554 references were obtained, 20 references were obtained from Cochrane and 661 references were obtained from Embase. Twenty-nine articles were selected based on abstract, content and study design. Randomised trials with higher levels of evidence were selected primarily /2011 $
2 Analysis of Evidence Imaging technique and lymph nodes status. All current international guidelines recommend a pre-treatment assessment of lymph node status (dimension, morphological and vascular pattern) based on imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) with contrast enhancement (1). However, these tools have low accuracy, with an evident discrepancy between the morphological appearance of the nodes and their final pathological status. In fact, approximately 25% of patients who were staged as node-negative preoperatively proved to have lymph node involvement at final histopathology (5). To overcome these deficiencies, several new techniques are currently being studied. One such technique is positronemission tomography (PET), which permits the study of metabolic processes in vivo, such as membrane metabolism and proliferation rate (6). Information regarding metabolic activity may also support the recognition of lymph node metastases that are morphologically normal. The most common used radiotracers are 18 F-fluorodeoxyglucose (FDG) and 11 C-choline. Some studies have suggested that combined PET-CT may have a role in the detection of nodal and distant metastases (6), but these results should be confirmed by further studies. At the moment, the evidence suggests that currently utilised imaging techniques are not able to predict pelvic lymph node involvement, especially in cases of small metastases or micrometastases. Lymphatic drainage of the bladder, distribution of LN metastases and techniques of PLND. A precise knowledge of the lymphatic drainage of the bladder is the first step in order to perform an appropriate lymphadenectomy during radical cystectomy. The primary contributions to the knowledge of bladder lymphatic drainage came from studies by Leadbetter and Cooper in 1950 (7). The lymphatic drainage from the bladder is separated into six different areas: (i) the visceral lymphatic plexus into the bladder wall, developing in the submucosa and extending into the muscular layer of the organ; (ii) the intercalated lymph nodes (which are juxtavesical lymph nodes located in the perivesical fat), divided into anterior, lateral and posterior groups; (iii) pelvic collecting trunks, which are intermediate lymph nodes to the external iliac and hypogastric lymph nodes; (iv) regional pelvic lymph nodes, which include nodes around the external iliac, hypogastric and sacral vessels; (v) lymphatic trunks leading from the regional pelvic lymph nodes and (vi) common iliac lymph nodes, which are around the common iliac vessels. The last site of lymph node drainage is probably the secondary site of metastasis, in an intermediate position between the pelvic and the aortocaval lymph nodes (7). Anatomical studies have revealed that the two most important sites of lymph node involvement are the external iliac and obturator lymph nodes. Smith and Whitmore reported that these sites of nodal metastases were involved in 74 and 65% of patients, respectively (8). They also demonstrated lymph node metastasis to the nodes around the common iliac vessels in 19% of patients. The need to extend lymph node dissection to a higher level remains controversial. The distribution of lymph node metastases was recently evaluated in a multicentre study in which an extended lymphadenectomy was performed in all patients with bladder cancer (9). This study demonstrated that positive lymph nodes were found most commonly in the obturator fossa and near the iliac vessels. It is interesting to note that approximately 16% of lymph node metastases also included nodes above the aortic bifurcation, while 8% involved the presacral region. Among the patients with lymph node metastases located within the limits of a standard dissection (below the bifurcation of the common iliac vessels), a considerable proportion had also nodal involvement at the level of the common iliac vessels and above the aortic bifurcation. The importance of an extended lymphadenectomy was also demonstrated by Bochner et al. (10), who found that 33% of patients with microscopic nodal involvement had metastasis to the common iliac nodes. Vazina et al. evaluated 176 ptxn0-1 patients who underwent radical cystectomy and PLND (11). Of 43 lymph node positive patients, metastases were found in the following anatomic sites: aortic bifurcation (4%), common iliac nodes (right side: 5.7%; left side: 8%), presacral nodes (5.1%), pelvic nodes (right side: 12%; left side: 14%), perivesical nodes (2.8%) and unspecified pelvic nodes (5.7%). In order to remove all potential sites for nodal metastases at the time of cystectomy, these studies support the need for a more extended bilateral lymphadenectomy with a higher extent of dissection that includes the common iliac lymph nodes, as well as removal of the presacral nodal lymph nodes. Mills et al. described the extended lymphadenectomy as a pelvic dissection that involves all nodal tissue around the common iliac bifurcation, including the internal iliac (and presacral), obturator fossa, external iliac and distal common iliac (12). The authors also recommended the removal of tissue over the common iliac bifurcation up to the point where the ureter crosses the iliac vessel. In contrast, Stein et al. defined an extended lymphadenectomy as a pelvic dissection that involves all lymph nodes around the aortic bifurcation and common iliac vessels (proximally), the circumflex iliac vein and lymph node of Cloquet (distally), the genitofemoral nerve (laterally), the hypogastric vessels (posteriorly) including the obturator fossa, the presciatic nodes bilaterally and the presacral lymph nodes (13). However, a recent study questioned whether extended lymphadenectomy would increase the morbidity in patients undergoing radical cystectomy (14). A total of 46 patients undergoing an extended pelvic lymph node dissection were compared to 46 patients undergoing a standard PLND. 272
3 Brunocilla et al: Radical Cystectomy with Bilateral Pelvic Iliac Lymphadenectomy for High-grade, Invasive Bladder Cancer (Short Review) Although the extended lymphadenectomy increased the operative duration by approximately 63 minutes, there was no statistically significant difference in perioperative mortality, early complications or the need for blood transfusions between the two groups. The authors concluded that despite an increase in the surgical procedure time, extended lymph node dissection did not cause significant adverse effects during the postoperative period. Prognostic factors in patients with lymph node involvement following radical treatment for bladder cancer. The prognosis for patients with lymph node metastasis undergoing radical cystectomy still remains poor; however optimum local control at the time of the initial treatment can be offered by radical cystectomy and extended PLND. The presence of lymph node involvement after radical cystectomy is related to an increased risk of tumour recurrence and progression (4, 15, 16). Nevertheless, more than 30% of patients demonstrate long-term survival following radical cystectomy (4). Pathological stage and tumour burden are now established prognostic factors of lymph node involvement (4, 17, 18). The final pathological stage remains one of the most important prognostic indicators for patients with node-positive disease following radical cystectomy (4, 16, 18). In a multivariate analysis, Vieweg et al. found that the extent of the primary bladder tumour remains an independent risk factor in patients with lymph node-positive tumours (16). The five-year survival probability in patients with organ-confined node-positive tumours was 46-58% compared to 22-30% in patients with extravescical, lymph node-positive disease (16, 18). Another important factor in patients with bladder cancer following radical cystectomy is represented by the tumour burden (number of positive lymph nodes or number of lymph nodes involved with tumour) (4, 8, 17-19). In the largest series of 244 lymph node-positive patients with a median follow-up period of 10 years, Bochner et al. showed that tumour burden is a strong prognostic factor regarding survival (20). Similarly, Konety et al. found that survival was significantly improved for patients with node-positive disease if the patients had four or fewer positive lymph nodes, compared to those with more than four positive lymph nodes (37 versus 13%, respectively) (21). Obviously, survival and recurrence are inversely related to an increasing tumour burden; furthermore, in this node-positive group of patients, if more than 11 lymph nodes were removed, improved survival with better local pelvic control of the tumour was observed. After a PLND, the number of lymph nodes removed is an important prognostic factor in bladder cancer. An important body of evidence suggests that a minimum number of lymph nodes should be removed and pathologically evaluated during radical cystectomy to identify patients with node metastasis (18, 19). The SEER database showed that only a minority of patients in a population-based analysis have more than four nodes removed with cystectomy (21, 22). The anatomical extent of node dissection was an important variable. However, several other factors such as the surgeon s skills, and comorbities may influence the number of nodes removed (22, 23). Poulsen et al. demonstrated that including the lymph nodes from the bifurcation of the common iliac vessels up to the level of the aortic bifurcation in the node dissection increased the median number of lymph nodes removed from 14 to 25, with a notable impact on survival in both node-negative and node-positive patients and with a reduced local recurrence rate (15). With 16 or more lymph nodes removed, Leissner et al. showed an improvement in five-year recurrence-free survival: from 63 to 85% in organconfined tumours, from 40 to 55% in pt3 tumours and from 25 to 53% in patients with at most five lymph node metastases (17). Nevertheless, the Will Rogers phenomenon should be taken into account when analysing prognosis results in such series (24). When large numbers of lymph nodes are removed, the likelihood of leaving behind undiscovered positive nodes is reduced and this results in a better prognosis for patients with an extended PLND when compared with patients undergoing a limited PLND who may still have undiscovered positive nodes. Several other studies have confirmed that the absolute number of positive nodes is the most important factor for patient outcome and survival. Five, six and eight positive lymph nodes have been described as a cut-off value (4, 18, 25). Subgroup analyses for all these studies have shown significantly better outcomes for patients with smaller absolute numbers of involved lymph nodes. Subsequently, the notion of lymph node density (LND), defined as the ratio of the number of positive nodes to the total number of nodes removed, arises from the combination of these two independent variables as prognostic factors (1-3). It has been demonstrated that LND has an independent prognostic significance in addition to the number of positive nodes, pathological tumour stage and adjuvant chemotherapy (4, 26). In a study by Stein et al., patients with lymph node density 20% had a 43% chance of ten-year recurrence-free survival compared with only 17% when LND was 20% (4). LND 20% also predicted decreased disease-specific survival in the series reported by Kassouf et al.: the five-year disease-free survival rate was 54.6% for patients with LND 20% versus 15.3% for patients with LND >20% (27). The influence of the extracapsular extension of the lymph node metastasis (perforation of the capsule by tumour tissue with extranodal growth) on the recurrence-free survival after radical cystectomy has recently been suggested. A study by Fleischmann et al. evaluated 101 patients who underwent radical cystectomy and extended PLND with curative intent and who were diagnosed postoperatively with lymph node- 273
4 positive disease (28). The authors demonstrated that patients with extracapsular extension had a higher risk of relapse as shown by the results of recurrence-free survival (12 months versus 60 months) and overall survival (16 months versus 60 months) compared with patients with intranodal metastases. In the multivariate analysis, extracapsular extension of lymph node metastases was the strongest negative predictor for recurrence-free survival (28). The use of LND in clinical trials with adjuvant therapy should be encouraged to assess the real impact of the extent of lymphadenectomy in the choice of treatment and to reduce the surgical bias. The incorporation of LND into the TNM system should also be considered. The oncological impact of the extent of PLND during radical cystectomy for bladder cancer. Retrospective studies suggest that limited PLND (external iliac vessels plus obturator fossa) is associated with suboptimal stages and poorer outcome for patients with node-positive and node-negative disease. Extended PLND may allow more accurate staging and removal of undetected micrometastases. This could improve the survival of patients with histopathological lymph node-positive and -negative disease. In a study by Dhar et al., patients staged preoperatively as N0 M0 without adjuvant therapy were compared (29); 336 patients had limited PLND and 332 had extended PLND. The five-year recurrence-free survival rate of patients with lymph node-positive disease was 7% for limited dissection and 35% for extended PLND. The five-year recurrence-free survival rate for pt2 pn0 cases was 67% for limited PLND and 77% for extended PLND, while the respective rates for pt3 pn0 were 23% and 57% (p<0.001). The five-year recurrence-free survival rate for pt2 pn0 2 was 63% for limited PLND and 71% for extended PLND; for pt3pn0 2 cases the respective rates were 19% and 49% (p<0.001). As noted above, extending the limits of the node dissection with an increased number of lymph nodes retrieved improves the survival for both lymph node-negative and node-positive patients, with a reduction in terms of local recurrence (15). In an analysis of over 20,000 patients with bladder cancer included in the SEER cancer registry, with 1,923 patients submitted to radical cystectomy, the strongest survival factor was the removal of lymph nodes at the time of surgery (after controlling for age, tumour stage, histology, chemotherapy and radiation therapy) (21). The risk of death was also significantly higher in patients with fewer than four lymph nodes removed at cystectomy. An extended PLND may have beneficial effects on tumour treatment but the associated risks should be considered. The risk for elderly patients, and especially for patients with comorbidities, needs to be taken into account in all therapeutic decisions. A study by Broessner et al. demonstrated that an extended lymph node dissection appears not to increase the complication rate during or after surgery despite a prolonged operation time (60 minutes longer for the extended PLND group compared with the limited PLND group) (14). Poulsen et al. reported no significant impact of the extent of lymph node dissection regarding mortality or lymphocele formation (15). The results of a multicentre prospective trial confirmed the longer operation time (approximately 60 minutes) for an extended approach, whereas none of the participating centres observed any significant adverse side-effects related to the extended PLND (9). Large prospective multicentre trials are needed to validate the influence of more extended PLND on diseasespecific survival. Conclusion Radical cystectomy with bilateral pelvic iliac lymphadenectomy is a standard treatment for high-grade, invasive bladder cancer, providing the best survival outcomes and the lowest local recurrence rates and low rates of surgical complications. The limits of the lymph node dissection required are still under debate. The literature evidence suggests that the template for PLND should include at least the regions of the external and internal iliac vessels together with the obturator fossa and should encompass the distal part and the bifurcation of the common iliac vessels on both sides. There is a growing body of evidence to support a more extended lymphadenectomy at the time of cystectomy in all patients who are appropriate surgical candidates; it appears that extended dissection may provide a survival advantage in both nodepositive and node-negative patients without significantly increasing the morbidity or mortality of the surgery. The extent of lymph node dissection and the concept of LND are still not standardised but may improve stratification of lymph node-positive patients following radical cystectomy and may become a useful prognostic variable in high-risk node-positive patients, even in terms of staging. References 1 Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A and Witjes JA: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 55: , Kaufman DS, Shipley WU and Feldman AS: Bladder cancer seminar. Lancet 374: , Karl A, Carroll PR, Gschwend JE, Knuchel R, Montorsi F, Stief CG and Studer UE: The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 55: , Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D and Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19: ,
5 Brunocilla et al: Radical Cystectomy with Bilateral Pelvic Iliac Lymphadenectomy for High-grade, Invasive Bladder Cancer (Short Review) 5 Mehrsai A, Mansoori D, Taheri MM, Sina A, Seraji A and Pourmand G: A comparison between clinical and pathologic staging in patients with bladder cancer. Urol J 1: 85-89, Powles T, Murray I, Brock C, Oliver T and Avril N: Molecular positron-emission tomography and PET/CT imaging in urological malignancies. Eur Urol 51: , Leadbetter WF and Cooper JF: Regional gland dissection for carcinoma of the bladder: a technique of one-stage cystectomy, gland dissection and bilateral ureteroenterostomy. J Urol 63: , Smith JA and Whitmore WF Jr.: Regional lymph node metastasis from bladder cancer. J Urol 126: , Leissner J, Ghoneim MA, Abol-Enein H, Thüroff JW, Franzaring L, Fisch M, Schulze H, Managadze G, Allhoff EP, el-baz MA, Kastendieck H, Buhtz P, Kropf S, Hohenfellner R and Wolf HK: Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 171: , Bochner BH, Cho C, Herr HW, Donat M, Kattan MW and Dalbagni G: Prospective packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol 172: , Vazina A, Dugi D, Shariat SF, Evans J, Link R and Lerner SP: Stage-specific lymph node metastasis mapping in radical cystectomy specimens. J Urol 171: , Mills RD, Fleischmann A and Studer UE: Radical cystectomy with an extended pelvic lymphadenectomy: rationale and results. Surg Oncol Clin N Am 16: , Stein JP: The role of lymphadenectomy in patients undergoing radical cystectomy for bladder cancer. Curr Oncol Rep 9: , Brössner C, Pycha A, Toth A, Mian C and Kuber W: Does extended lymphadenectomy increase the morbidity of radical cystectomy? BJU Int 93: 64-66, Poulsen AL, Horn T and Steven K: Radical cystectomy: extending limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 160: , Vieweg J, Gschwend JE, Herr HW and Fair WR: The impact of primary stage on survival in patients with lymph node-positive bladder cancer. J Urol 161: 72-76, Leissner J, Hohenfellner R, Thuroff JW and Wolf HK: Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 85: , Stein JP, Cai J, Groshen S and Skinner DG: Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: the concept of lymph node density. J Urol 170: 35-41, Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, Weaver AL, Karnes RJ and Zinche H: Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy. Cancer 97: , Bochner BH, Herr HW and Reuter VE: Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 166: , Konety BR, Joslyn SA and O Donnell MA: Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the surveillance, epidemiology and end results program data base. J Urol 169: , Hollenbeck BK, Ye Z, Wong SL, Montie JE and Birkmeyer JD: Hospital lymph node counts and survival after radical cystectomy. Cancer 112: , Kulkarni GS, Finelli A, Lockwood G, Saravanan A, Evans A, Jewett MA, Trachtenberg J, Robinette M and Fleshner NE: Effect of healthcare provider characteristics on nodal yield at radical cystectomy. Urology 72: , Feinstein AR, Sosin DM and Wells CK: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312: , Lerner SP, Skinner DG, Lieskovsky G, Boyd SD, Groshen SL, Ziogas A, Skinner E, Nichols P and Hopwood B: The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol 149: , Herr HW: Superiority of ratio-based lymph node staging for bladder cancer. J Urol 169: , Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP and Kamat AM: Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 26: , Fleischmann A, Thalmann GN, Markwalder R and Studer UE: Prognostic implications of extracapsular extension of pelvic lymph node metastases in urothelial carcinoma of the bladder. Am J Surg Pathol 29: 89-95, Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S and Studer UE: Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 179: , Received October 24, 2010 Revised November 21, 2010 Accepted November 23,
Lymphadenectomy with Cystectomy: Is It Necessary
European Urology European Urology 46 (2004) 457 461 Lymphadenectomy with Cystectomy: Is It Necessary and What Is Its Extent? Mohamed A. Ghoneim *, Hassan Abol-Enein Urology & Nephrology Center, Gomhouria
More informationA Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density
Clinical Urology TCC of the Bladder and Lymph Node Density International Braz J Urol Vol. 32 (5): 536-549, September - October, 2006 A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma
More informationRole of Pelvic Lymphadenectomy in the Treatment of Bladder Cancer: A Mini Review
www.kjurology.org DOI:10.4111/kju.2010.51.6.371 Review Article Role of Pelvic Lymphadenectomy in the Treatment of Bladder Cancer: A Mini Review Ja Hyeon Ku Department of Urology, Seoul National University
More informationThe Extent of Lymphadenectomy at the Time of Radical Cystectomy for Bladder Cancer and its Impact on Prognosis and Survival
Review Article TheScientificWorldJOURNAL (2005) 5, 891 901 ISSN 1537-744X; DOI 10.1100/tsw.2005.115 The Extent of Lymphadenectomy at the Time of Radical Cystectomy for Bladder Cancer and its Impact on
More informationNodal staging and lymphadenectomy in patients undergoing radical cystectomy
37 Artigos Internacionais Nodal staging and lymphadenectomy in patients undergoing radical cystectomy Fredrik Liedberg, Wiking Månsson Department of Urology, Lund University Hospital, Lund, Sweden Introduction
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationOde to a node Lymph node dissec3on in prostate and bladder cancer
5/26/10 Ode to a node Lymph node dissec3on in prostate and bladder cancer Anthony Koupparis 1 Introduc3on prostate cancer PLND most accurate and reliable staging method for LNI Imaging techniques have
More informationDoes the Extent of Lymphadenectomy in Radical Cystectomy for Bladder Cancer Influence Disease-Free Survival? A Prospective Single-Center Study
EUROPEAN UROLOGY 60 (2011) 572 577 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Does the Extent of Lymphadenectomy in Radical Cystectomy for Bladder Cancer
More information346
EXTENDED LYMPHADENECTOMY IN BLADDER CANCER DURING RADICAL CYSTECTOMY: BENEFIT AND MORBIDITY Islam Mohiedden M, Diab El-Sayed M, Reda Mohamed S, Saad A M Al Qady, Department of Urology, Zagazig University,
More informationInvasive Bladder Transitional Cell Carcinoma OBJECTIVES
Invasive Bladder Transitional Cell Carcinoma UBC Urology Grand Rounds 7 September 2005 John Morrell R5 OBJECTIVES Review role of lymphadenectomy Review role of chemotherapy Review results of bimodal bladder
More informationConclusions. Keywords
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy Pascal Zehnder*, Urs E. Studer,
More informationRadical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
More informationExtent of Pelvic Lymph Node Dissection During Radical Cystectomy: Is Bigger Better?
ManageMent Review Extent of Pelvic Lymph Node Dissection During Radical Cystectomy: Is Bigger Better? Debasish Sundi, MD, 1 Robert S. Svatek, MD, MSCI, 2 Matthew E. Nielsen, MD, MS, 3 Mark P. Schoenberg,
More informationDoes skip metastasis or other lymph node parameters have additional effects on survival of patients undergoing radical cystectomy for bladder cancer?
Original Article - Urological Oncology Korean J Urol 2015;56:357-364. pissn 2005-6737 eissn 2005-6745 Does skip metastasis or other lymph node parameters have additional effects on survival of patients
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationEUROPEAN UROLOGY 60 (2011)
EUROPEAN UROLOGY 60 (2011) 946 952 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Bladder Cancer Editorial by Simon P. Kim and R. Jeffrey Karnes on pp. 953
More informationReview Article Lymphadenectomy in Management of Invasive Bladder Cancer
Hindawi Publishing Corporation International Journal of Surgical Oncology Volume 2011, Article ID 758189, 9 pages doi:10.1155/2011/758189 Review Article Lymphadenectomy in Management of Invasive Bladder
More informationLymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic
Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of
More informationLymph node dissection: how much is enough?
1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive
More informationSang Eun Lee, Hakmin Lee, Hyun Hwan Sung, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han-Yong Choi, Byong Chang Jeong
Korean J Urol Oncol 2016;14(3):124129 Original Article Comparisons between Standard and Extended Pelvic Lymph Node Dissections During Radical Cystectomy in Patients with Bladder Cancer: Emphasis on Staging
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationClinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
More informationRole and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017
Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients
More informationThe Feasibility of Robot-Assisted Laparoscopic Radical Cystectomy with Pelvic Lymphadenectomy: from the Viewpoint of Extended Pelvic Lymphadenectomy
The Feasibility of Robot-Assisted Laparoscopic Radical Cystectomy with Pelvic Lymphadenectomy: from the Viewpoint of Extended Pelvic Lymphadenectomy Seung Chul Kang, Sung Gu Kang, Hoon Choi, Young Hwii
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationBJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.
2010 THE AUTHORS; 2010 Urological Oncology LYMPH NODE STATUS IN PT0 BLADDER CANCER KAAG ET AL. BJUI Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationOpen Radical Cystectomy Tips and Tricks in Males and Females
Open Radical Cystectomy Tips and Tricks in Males and Females Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine
More informationRadical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients
EUROPEAN UROLOGY 61 (2012) 1039 1047 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationNeoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney
More informationDebate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer
Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Kala Sridhar, MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital GU Medical Oncology Site Group Head Associate Professor, University
More informationLymph Node Density Affects Cancer-Specific Survival in Patients with Lymph Node Positive Urothelial Bladder Cancer Following Radical Cystectomy
EUROPEAN UROLOGY 59 (2011) 712 718 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Bladder Cancer Editorial by James W.F. Catto on pp. 719 720 of this issue
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationUrology Department, Inselspital, Bern, Switzerland. Key Words. Extended pelvic lymph node dissection Bladder cancer Prostate cancer
The Oncologist The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Genitourinary Cancer Indications,
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationEarly radical cystectomy in NMIBC Marko Babjuk
Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationL approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo
L approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo Paolo Gontero Division of Urology Città della Salute e della Scienza
More informationLymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer
EUROPEAN UROLOGY 60 (2011) 776 783 available at www.sciencedirect.com journal homepage: www.europeanurology.com Collaborative Review Urothelial Cancer Lymphadenectomy at the Time of Nephroureterectomy
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Outcome of Open Radical Cystectomy and Ileal Conduit: A Single Center Experience Mahesh Kalloli
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationINVASIVE BLADDER CANCER
INVASIVE BLADDER CANCER - Aspects on staging and prognosis Liedberg, Fredrik 2006 Link to publication Citation for published version (APA): Liedberg, F. (2006). INVASIVE BLADDER CANCER - Aspects on staging
More informationREVIEW. Patterns of recurrence of bladder carcinoma following radical cystectomy
Cancer Imaging (2003) 3, 96 100 DOI: 10.1102/1470-7330.2003.0009 CI REVIEW Patterns of recurrence of bladder carcinoma following radical cystectomy D M Koh and J E Husband Academic Department of Radiology,
More informationHaijun Zhou, Jae Y Ro, Luan D Truong, Alberto G Ayala, Steven S Shen
Am J Clin Exp Urol 2014;2(2):156-160 www.ajceu.us /ISSN:2330-1910/AJCEU0000048 Original Article Intraoperative frozen section evaluation of ureteral and urethral margins: studies of 203 consecutive radical
More informationAnterior urethra sparing cystoprostatectomy for bladder cancer: a 10 year, single center experience
DOI 10.1186/s40064-015-1200-7 RESEARCH Open Access Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10 year, single center experience Nozomi Hayakawa 1,2*, Nobuyuki Kikuno 1,2, Hiroki
More informationROBOTIC VS OPEN RADICAL CYSTECTOMY
ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to
More informationOptimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder
Jpn J Clin Oncol 2002;32(1)14 18 Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder Isao Hara, Hideaki Miyake, Shoji Hara, Akinobu Gotoh, Hiroshi
More informationGood Outcome for Patients with Few Lymph Node Metastases After Radical Retropubic Prostatectomy
european urology 54 (2008) 344 352 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Good Outcome for Patients with Few Lymph Node Metastases After Radical Retropubic
More informationImpact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy
Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationABSTRACT INTRODUCTION
/, 2017, Vol. 8, (No.51), pp: 89228-89235 Impact of preoperative diagnostic TURBT on progression-free survival in patients with pathological high-grade, stage T3/T4 bladder urothelial carcinoma Haichao
More informationRadical cystectomy with pelvic lymphadenectomy: pathologic, operative and morbidity outcomes in a Brazilian cohort
ORIGINAL ARTICLE Vol. 42 (3): 431-437, May - June, 2016 doi: 10.1590/S1677-5538.IBJU.2015.0380 Radical cystectomy with pelvic lymphadenectomy: pathologic, operative and morbidity outcomes in a Brazilian
More informationThe impact of the extent of lymphadenectomy on oncological outcomes in patients. undergoing radical cystectomy for bladder cancer:
This is the authors' final version, post peer-review, of an article published in Eur Urol 2014;doi: 10.1016/j.eururo.2014.05.031. The definitive version is available from www.sciencedirect.com The impact
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationGUIDELINES ON PENILE CANCER
GUIDELINES ON PENILE CANCER (Text updated March 2005) G. Pizzocaro (chairman), F. Algaba, S. Horenblas, H. van der Poel, E. Solsona, S. Tana, N. Watkin 58 Penile Cancer Eur Urol 2004;46(1);1-8 Introduction
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More informationSurgeons Perspective: LN as a Draining Pattern. Jose A. Karam, MD, FACS Associate Professor Department of Urology
Surgeons Perspective: LN as a Draining Pattern Jose A. Karam, MD, FACS Associate Professor Department of Urology Disclosures EMD Serono, Pfizer, Novartis: Advisory board/consultant Disclosures I perform
More informationDr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate
Dr. Tareq Salah Ahmed,MD,ESMO Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate 1 st Assiut Urology department conference,marsa Alam 3 rd February 2015 Bladder cancer
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationLong-Term Oncologic Outcomes after Radical Cystectomy for Bladder Cancer at a Single Institution
ORIGINAL ARTICLE Oncology & Hematology http://dx.doi.org/0.3346/jkms.204.29.5.669 J Korean Med Sci 204; 29: 669675 LongTerm Oncologic Outcomes after Radical Cystectomy for Bladder Cancer at a Single Institution
More informationRadical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients
Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported
More informationDiagnosis and classification
Patient Information English 2 Diagnosis and classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour is present.
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationShould the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer
Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology
More information6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationincluding total number of retrieved and positive LNs in each area of dissection, operative duration and complications.
2009 THE AUTHORS. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Laparoscopic and Robotic Urology COMMON ILIAC LYMPH NODE DISSECTION DURING RALP KATZ ET AL. BJUI BJU INTERNATIONAL Lymph node dissection during
More informationClinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment
EUROPEAN UROLOGY 61 (2012) 237 242 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Bladder Cancer Editorial by Alexandre R. Zlotta on pp. 243 244 of this
More informationInfluence of stage discrepancy on outcome in. in patients treated with radical cystectomy.
Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationExtranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis
EUROPEAN UROLOGY 64 (2013) 837 845 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients
More informationProposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationLYMPHATIC DRAINAGE IN THE HEAD & NECK
LYMPHATIC DRAINAGE IN THE HEAD & NECK Like other parts of the body, the head and neck contains lymph nodes (commonly called glands). Which form part of the overall Lymphatic Drainage system of the body.
More informationRole of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer
Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer Henry Goodfellow, Zaid Viney*, Paul Hughes*, Sheila Rankin*, Giles Rottenberg*,
More informationUrothelial bladder cancer is a common neoplasm of the
Value of C-Choline PET and Contrast-Enhanced CT for Staging of Bladder Cancer: Correlation with Histopathologic Findings Maria Picchio* 1, Uwe Treiber* 2, Ambros J. Beer 3, Stefan Metz 3, Patrick Bössner
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationPartial Cystectomy for Invasive Bladder Cancer
European Urology Supplements European Urology Supplements 4 (2005) 67 71 Partial Cystectomy for Invasive Bladder Cancer Gerald H. Mickisch* Center of Operative Urology Bremen, Academic Hospital Bremen
More informationPure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder
Safini et al. 31 case Series report peer Reviewed open OPEN ACCESS Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Fatima Safini, Hassan Jouhadi, Meriem Elbachiri,
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationDebate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.
Debate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.. Eighth European International Kidney Cancer Symposium Budapest 03-04 May 2013 The role of LND In organ confined
More informationResearch Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer
More informationKoji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto
Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in
More informationESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data
ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data David Cibula Gynecologic Oncology Centre General University Hospital
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More informationGUIDELINES ON RENAL CELL CANCER
20 G. Mickisch (chairman), J. Carballido, S. Hellsten, H. Schulze, H. Mensink Eur Urol 2001;40(3):252-255 Introduction is characterised by a constant rise in incidence over the last 50 years, with a predominance
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationA comparison of preliminary oncologic outcome and postoperative complications between patients undergoing either open or robotic radical cystectomy
ORIGINAL ARTICLE Vol. 42 (4): 663-670, July - August, 2016 doi: 10.1590/S1677-5538.IBJU.2015.0393 A comparison of preliminary oncologic outcome and postoperative complications between patients undergoing
More informationThe Role of Surgery in Metastatic Bladder Cancer. Maurizio Brausi Chairman ESOU Modena, ITALY
The Role of Surgery in Metastatic Bladder Cancer Maurizio Brausi Chairman ESOU Modena, ITALY Disclosures No relevant to this presentation Metastatic/Unresectable BC: Definition «Bladder cancer invading
More informationLocal Excision for early rectal cancer
Local Excision for early rectal cancer M. Trompetto, E. Ganio, G. Clerico, A. Realis Luc, RJ Nicholls Colorectal Eporediensis Centre Clinica S. Rita Vercelli Gruppo Policlinico di Monza Mortality Morbidity
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More information